Apr. 11 at 1:48 PM
$YDES
The EG BioMed merger MOU signed in January 2026 integrates DNA methylation diagnostics, real-world clinical data, and AI-driven biomarker analytics into one oncology platform. This isn’t a concept stock anymore — YDES already has FDA-cleared Exovisse contact lenses generating revenue, plus a CAP-accredited lab in the U.S. running commercial cancer tests.
👉Click to view @NasdaqPulse for timely updates amid the volatility.
Institutional ownership? Only 0.20%. That‘s a PROBLEM for most stocks. For me? That’s OPPORTUNITY. Institutions will be forced to buy when the merger closes. Retail owns 96% of the float right now. When big money rotates in, the move will be violent.
Cash position is solid. No long-term debt. Enterprise value is actually HIGHER than market cap —
$841M EV vs
$441M market cap.
The bear thesis: “Revenue is zero” — except it’s not. They have clinical trial drug distribution revenue, plus eye care product sales.
